| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Martin Hohenegger | Q42849484 |
| P2860 | cites work | Hemolytic uremic syndrome and rhabdomyolysis in a patient with succinate coenzyme Q reductase (complex II) deficiency. | Q33396047 |
| Myoglobinuria | Q33829482 | ||
| Rhabdomyolysis: a review | Q33957693 | ||
| The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome | Q34220515 | ||
| Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma | Q34580897 | ||
| Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. | Q35620025 | ||
| Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition | Q36800953 | ||
| Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors | Q36807146 | ||
| Molecular basis for sunitinib efficacy and future clinical development | Q36906667 | ||
| Daptomycin: a review 4 years after first approval | Q36972980 | ||
| New insights into mechanisms of statin-associated myotoxicity | Q37074941 | ||
| Cardiotoxicity induced by tyrosine kinase inhibitors | Q37593059 | ||
| Calpains, skeletal muscle function and exercise | Q37605922 | ||
| Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features | Q37713742 | ||
| Cardiotoxicity associated with targeting kinase pathways in cancer | Q37823035 | ||
| Early fluid resuscitation in patients with rhabdomyolysis | Q37876684 | ||
| Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity | Q37880633 | ||
| Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase | Q39889569 | ||
| Administration interval and daptomycin toxicity: a case report of rhabdomyolysis. | Q42751892 | ||
| Dantrolene for the treatment of MDMA toxicity. | Q42868710 | ||
| Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases | Q42930020 | ||
| Effect of daptomycin on primary rat muscle cell cultures in vitro | Q43103419 | ||
| Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). | Q43229133 | ||
| Impaired fatty acid oxidation in propofol infusion syndrome | Q43738514 | ||
| Nifedipine Diminishes Exercise-Induced Muscle Damage in Mouse | Q44185383 | ||
| Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. | Q45969377 | ||
| Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study. | Q45992466 | ||
| Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor | Q46061131 | ||
| Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin | Q46466772 | ||
| Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells | Q46508413 | ||
| Imatinib as a possible cause of severe rhabdomyolysis | Q46530425 | ||
| Rhabdomyolysis and acute renal failure in a patient treated with daptomycin | Q46892799 | ||
| Propofol infusion syndrome--a critical incident report highlighting the danger of reexposure | Q48279051 | ||
| Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectance spectroscopy. | Q51419361 | ||
| Short-term propofol infusions in children. | Q51441578 | ||
| Rhabdomyolysis in association with Duchenne's muscular dystrophy. | Q51452562 | ||
| Rhabdomyolysis from erlotinib: a case report. | Q54571854 | ||
| Myoplasmic Ca2+ concentration during exertional rhabdomyolysis | Q72540471 | ||
| Rhabdomyolysis and myoglobinuric renal failure in trauma and surgical patients: a review | Q74667348 | ||
| [Propofol infusion syndrome] | Q80789594 | ||
| Early-onset rhabdomyolysis related to daptomycin use | Q81096875 | ||
| Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma | Q83152666 | ||
| Rhabdomyolysis during therapy with daptomycin | Q83358521 | ||
| Photodistributed eruption with rhabdomyolisis due to leflunomide | Q84507315 | ||
| Dantrolene for severe rhabdomyolysis in Staphylococcus aureus toxic shock syndrome | Q85036313 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P433 | issue | 3 | |
| P921 | main subject | tissue | Q40397 |
| mechanism of action | Q3271540 | ||
| rhabdomyolysis | Q917069 | ||
| enzyme inhibitor | Q427492 | ||
| human musculoskeletal system | Q726543 | ||
| contractile proteins | Q69633297 | ||
| P304 | page(s) | 335-339 | |
| P577 | publication date | 2012-05-05 | |
| 2012-06-01 | |||
| P1433 | published in | Current Opinion in Pharmacology | Q3007702 |
| P1476 | title | Drug induced rhabdomyolysis | |
| P478 | volume | 12 |
| Q40966148 | A case of exercise induced rhabdomyolysis from calf raises |
| Q92714602 | A case of gabapentin overdose induced rhabdomyolysis requiring renal replacement therapy |
| Q26746093 | Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice |
| Q57494518 | Combination of Antidepressant and Alcohol Intake as a Potential Risk Factor for Rhabdomyolysis |
| Q89104302 | Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management |
| Q35281940 | Drugs in induction and treatment of idiopathic inflammatory myopathies |
| Q39004218 | Improvement of hepatic bioavailability as a new step for the future of statin |
| Q59640070 | Management of Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia |
| Q38392679 | Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia |
| Q27020935 | Phenotype standardization for statin-induced myotoxicity |
| Q41945125 | Postoperative rhabdomyolysis: a completely localised and symmetrical phenomenon? |
| Q44914071 | Rhabdomyolysis and creatine kinase elevation |
| Q38691963 | Rhabdomyolysis induced by antiepileptic drugs: characteristics, treatment and prognosis. |
| Q26765518 | Role of endoplasmic reticulum stress in drug-induced toxicity |
| Q104755192 | [CME: Elevated Creatine Kinase as a Diagnostic Parameter of Rhabdomyolysis] |
Search more.